Search

Your search keyword '"Breakthrough Breast Cancer Centre"' showing total 40 results

Search Constraints

Start Over You searched for: Author "Breakthrough Breast Cancer Centre" Remove constraint Author: "Breakthrough Breast Cancer Centre"
40 results on '"Breakthrough Breast Cancer Centre"'

Search Results

1. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

2. Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue

3. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

4. ESR1 mutations in metastatic lobular breast cancer patients

5. High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast

6. The Dilemma of HER2 Double-equivocal Breast Carcinomas

7. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors

8. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures

9. Somatic mutations reveal asymmetric cellular dynamics in the early human embryo

10. Landscape of somatic mutations in 560 breast cancer whole-genome sequences

11. Genomic landscape of adenoid cystic carcinoma of the breast

12. GD3 synthase expression enhances proliferation and tumor growth of MDA-MB-231 breast cancer cells through c-Met activation

13. Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study

14. Synergistic activity of letrozole and sorafenib on breast cancer cells

15. Roles for p53 and p73 during oligodendrocyte development

16. HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.

17. Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors.

18. Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome.

19. Human Peritoneal Mesothelial Cells Display Phagocytic and Antigen-Presenting Functions to Contribute to Intraperitoneal Immunity.

20. Association of Active and Sedentary Behaviors with Postmenopausal Estrogen Metabolism.

21. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.

22. Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis.

23. Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer.

24. Combined associations of genetic and environmental risk factors: implications for prevention of breast cancer.

25. mTOR inhibitors in advanced breast cancer: ready for prime time?

26. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.

27. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

28. Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones.

29. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.

30. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.

31. Predicting response to cytotoxic drugs--the endocrine part of the story.

32. EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.

33. The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.

34. Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise?

35. The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.

36. Mechanisms of disease: angiogenesis and the management of breast cancer.

37. Epigenetic inactivation implies a tumor suppressor function in hematologic malignancies for Polo-like kinase 2 but not Polo-like kinase 3.

38. Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies.

39. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation.

40. The mammary gland "side population": a putative stem/progenitor cell marker?

Catalog

Books, media, physical & digital resources